Can-Fite BioPharma (NYSE:CANF) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Can-Fite BioPharma (NYSE:CANF) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $18.00 target price on the stock.

A number of other equities analysts also recently issued reports on CANF. EF Hutton Acquisition Co. I upgraded Can-Fite BioPharma to a “strong-buy” rating in a research report on Wednesday, July 17th. StockNews.com lowered Can-Fite BioPharma from a “hold” rating to a “sell” rating in a research report on Wednesday, October 30th.

Can-Fite BioPharma Stock Performance

CANF stock opened at $2.10 on Tuesday. Can-Fite BioPharma has a one year low of $1.83 and a one year high of $4.69. The firm’s fifty day moving average is $2.26 and its 200 day moving average is $2.52. The firm has a market cap of $7.43 million, a PE ratio of -1.17 and a beta of 1.39.

Hedge Funds Weigh In On Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC boosted its holdings in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the period. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.